Welcome to our dedicated page for Applied Therapeutics news (Ticker: APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.
Applied Therapeutics, Inc. (APLT) is a clinical-stage biopharmaceutical company pioneering novel therapies for rare metabolic disorders and diabetic complications. This page serves as the definitive source for official news and developments related to their innovative aldose reductase inhibitor (ARI) pipeline.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements. Our curated collection includes press releases detailing phase updates for govorestat (Galactosemia/SORD Deficiency), AT-001 (diabetic cardiomyopathy), and AT-003 (diabetic retinopathy), along with partnership announcements and research publications.
All content is rigorously verified to ensure accuracy and relevance, providing a trustworthy resource for tracking APLT's progress in addressing high unmet medical needs. Bookmark this page for streamlined access to critical updates about their CNS-penetrant therapies and regulatory engagements.
FAQ
What is the current stock price of Applied Therapeutics (APLT)?
What is the market cap of Applied Therapeutics (APLT)?
